A Phase 1 b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer

Brief description of study

The purpose of the study is to evaluate the antitumor activity and safety/tolerability of etruma-based combination therapy in participants with metastatic colorectal cancer (mCRC).There are three investigational products administered in this study depending on the treatment arm: AB928 (referred to as etrumadenant and “etruma” throughout), zimberelimab (AB122; referred to as “zim” throughout), AB680. The three investigational drugs have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.


Clinical Study Identifier: s20-01717
ClinicalTrials.gov Identifier: NCT04660812
Principal Investigator: Paul E. Oberstein.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.